SOPHION BIOSCIENCE A/S: Financial statements 2024
CVR: 10021065
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
SOPHION BIOSCIENCE A/S (CVR 10021065) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 119,621,000 and a net result of DKK 39,127,000 compared with DKK 28,022,000 the year before. That is an increase of 105,942.3% compared with the year before. Equity in the 2024 report amounted to DKK 191,970,000. The solvency ratio was 77.8%. The company had 71 employees in the financial year.
- Gross Profit
- DKK 119,621,000
- Profit/Loss
- DKK 39,127,000
- Equity
- DKK 191,970,000
- Total Assets
- DKK 246,788,000
- Employees
- 71
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 119.6 mio. | 39.1 mio. | 192 mio. | 71 |
| 2023 | - | 113 t. | 28 mio. | 157 mio. | 57 |
| 2022 | - | 117.7 mio. | 44.4 mio. | 188.1 mio. | 48 |
| 2021 | - | 98.3 mio. | 36.3 mio. | 143.8 mio. | 41 |
| 2020 | - | 77.5 mio. | 25.2 mio. | 106.5 mio. | 35 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
As of September 1, 2024, Michel Krall Jürgens is registered as adm. dir. of SOPHION BIOSCIENCE A/S.
As of August 31, 2024, Thais Taaning Johansen has stepped down as adm. dir. of SOPHION BIOSCIENCE A/S.
SOPHION BIOSCIENCE A/S has published its annual report for 2023. Gross profit came to DKK 112,805, and the net result was DKK 28,022,000.
About SOPHION BIOSCIENCE A/S
SOPHION BIOSCIENCE A/S is a Danish company of the type Aktieselskab based in Ballerup, founded in 2000. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named IONS A/S and KR 228 A/S. The management consists of Michel Krall Jürgens. The board consists of Harald Høegh (chair), Eirik Lauglo, Gustaf Peter Reinhold von Ehrenheim and Peter Max. The company is owned by Sapphire Bioscience Holding ApS. The company has 86 employees (2026). In 2025, the company reported a gross profit of DKK 102,112,000 and a net result of DKK 4,354,000 compared with DKK 39,127,000 the year before. Equity in the 2025 report amounted to DKK 178,418,000.